SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
ANRO

Alto Neuroscience, Inc. (ANRO)

NYSE: ANRO · USD
Healthcare · Biotechnology
$25.37-$1.14 (-4.30%)
 
Market cap
$1.02B
Insider Score
Analyst consensus
Market Cap$1.02B+79.3%
Revenue (ttm)n/a
Net Income-$95.18M
EPS-$2.32
Shares Out40.11M
PE Ration/a
Forward PE-8.58
Dividendn/a
Ex-Dividend Daten/a
Volume522,526
Open$25.76
Previous Close$26.51
Day's Range$24.40 - $26.48
52-Week Range$12.51 - $37.48
Beta1.45
AnalystsStrong Buy
Price Target$38.67(+52.41%)
Earnings DateNov 10, 2026

About ANRO

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clinical trial to treat patients with major depressive disorder (MDD); ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor that is in Phase 2 proof-of-concept (POC) trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist, which is in Phase 2 POC trial to treat patients with MDD and higher levels of anhedonia; ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor that is in Phase 1 clinical trial for the treatment of MDD; and ALTO-208, a fixed-dose combination of pramipexole and aprepitant, an antiemetic, neurokinin-1 (NK-1) receptor antagonist for patients with Parkinson's disease for patients with Parkinson's disease. The company was incorporated in 2019 and is headquartered in Mountain View, California.

Address
650 Castro Street, Mountain View, CA, 94041, United States
Market Cap
1.02 billion
Employees
68
Industrial Classification
Biotechnology

What Are Insiders Doing?

Open-market buy / sell balanceNet Selling
Sold
$5.64M
Bought
$0

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Analyst consensus

Moderate Buy
2 Buy0 Hold0 SellAvg target $36.50 (+43.9%)

2 firms rating ANRO in the last 3 months, one vote each. Issuer-paid research is not counted.

1 Day
-4.30%
5 Days
-14.12%
1 Month
+14.28%
6 Months
+19.56%
1 Year
+79.29%

$ANRO stock is featured in our Insider Score Rankings, and Insider Trades datasets.

→ All Stock Lists

Recently reported changes in ANRO holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by ANRO's directors and management

Net Shares Purchased by Insiders−200k−100k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

ANRO Estimated quarterly lobbying spending

Source: U.S. Senate LDA

U.S. Patents

New ANRO patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to ANRO from public contracts

Source: USAspending.gov

Bull Case vs Bear Case

AI-generated from ANRO’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
48% of score
0
Analyst Ratings
32% of score
99
News & Sentiment
20% of score
72

News check: Analyst upgrade to Buy, positive price targets, and upcoming clinical catalysts outweigh insider selling and valuation concerns.

Recent Insider Activity

Buys
0
Sells
8
Buy Value
$0
Distinct Buyers
0

Insider Score Trend Over Time

-22.0 since Oct 2
0255075100Oct 2 — Insider Score 22.0Oct 3 — Insider Score 0.0Oct 4 — Insider Score 0.0Oct 2Oct 3Oct 4

Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

PSILAdvisorShares Psychedelics ETF5.15%
DWASInvesco Dorsey Wright SmallCap Momentum ETF1.73%
IBRNiShares Neuroscience and Healthcare ETF1.60%
XPHState Street SPDR S&P Pharmaceuticals ETF1.48%
PTHInvesco Dorsey Wright Healthcare Momentum ETF1.27%
BBCVirtus Biotech Clinical Trials ETF1.07%
SBIOALPS Medical Breakthroughs ETF0.79%
TDNAT. Rowe Price Biotech ETF0.40%
BUSMEA Series Trust - EA Bridgeway Ultra-Small Company Market ETF0.26%
IWCiShares Micro-Cap ETF0.25%
PILLDirexion Daily Pharmaceutical & Medical Bull 3X ETF0.21%
OPTZOptimize Strategy Index ETF0.16%

Weight is the stock’s share of each fund’s holdings.